Johan Vansteenkiste
Impact in
- Oncology top 0.05%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 137
- Lung Cancer Research Studies 63
- Cancer Immunotherapy and Biomarkers 51
- Colorectal Cancer Treatments and Studies 40
-
- Lung Cancer Treatments and Mutations 122
- Lung Cancer Diagnosis and Treatment 42
- Co-authors
- Solange PetersSuresh SenanKeith M. KerrKeunchil ParkJoachim von PawelFabrice BarlésiMatthijs OudkerkDavid Waller
- Journals
- Journal of Clinical Oncology (37 papers)Journal of Thoracic Oncology (32 papers)Annals of Oncology (31 papers)Lung Cancer (19 papers)ESMO Open (3 papers)
- Partner nations
- BelgiumUnited StatesSpain
In The Last Decade
Johan Vansteenkiste
168 papers receiving 18.3k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Oncology 12.9k
- Pulmonary and Respiratory Medicine 13.2k
- Cancer Research 2.9k
- Immunology 1.7k
- Molecular Biology 4.4k
Countries citing papers authored by Johan Vansteenkiste
This map shows the geographic impact of Johan Vansteenkiste's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Vansteenkiste with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Vansteenkiste more than expected).
Fields of papers citing papers by Johan Vansteenkiste
This network shows the impact of papers produced by Johan Vansteenkiste. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Vansteenkiste. The network helps show where Johan Vansteenkiste may publish in the future.
Co-authors
The 25 scholars most cited alongside Johan Vansteenkiste, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 16 | |
| 2 | 2019 | 13 | |
| 3 | 2019 | 38 | |
| 4 | Phenotype molding of stromal cells in the lung tumor microenvironment Hit paper breakdown → | 2018 | 1037 |
| 5 | 2018 | 1 | |
| 6 | 2018 | 5 | |
| 7 | 2017 | 12 | |
| 8 | 2015 | 64 | |
| 9 | First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicentre academic phase II study in caucasian patients (pts) (NCT00339586) | 2011 | 1 |
| 10 | 2011 | 23 | |
| 11 | MAGE-A3 GENE EXPRESSION FREQUENCY AND DEMOGRAPHY DATA OF STAGE IB-IIIA NSCLC PATIENTS FROM ONGOING MAGRIT PHASE III TRIAL EVALUATING MAGE-A3 ANTIGEN SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT | 2010 | 6 |
| 12 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | 2009 | 1 |
| 13 | MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized | 2009 | 2 |
| 14 | Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer Hit paper breakdown → | 2008 | 2487 |
| 15 | GENE EXPRESSION SIGNATURE IS A POTENTIAL PREDICTIVE FACTOR FOR EFFICACY OF MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC) | 2008 | 2 |
| 16 | 2006 | 12 | |
| 17 | A novel time factor, the SER (Start of any treatment and the End of Radiotherapy), is predictive for local control and survival in a systematic overview of combined chest radiotherapy and chemotherapy for limited stage small cell lung cancer | 2004 | 4 |
| 18 | Early versus late chest radiotherapy for limited stage small cell lung cancer: a systematic review and meta-analysis | 2004 | 8 |
| 19 | Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2003 | 2392 |
| 20 | 2000 | 32 |
About Johan Vansteenkiste
Johan Vansteenkiste is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Pathology and Forensic Medicine, having authored 169 papers that have together received 18.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (122 papers), Lung Cancer Research Studies (63 papers), Cancer Immunotherapy and Biomarkers (51 papers), Lung Cancer Diagnosis and Treatment (42 papers), Colorectal Cancer Treatments and Studies (40 papers), Cancer Genomics and Diagnostics (23 papers), Immunotherapy and Immune Responses (10 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers). The work is most often cited by research in Oncology (12.9k citations), Pulmonary and Respiratory Medicine (13.2k citations), Cancer Research (2.9k citations), Immunology (1.7k citations) and Molecular Biology (4.4k citations). Johan Vansteenkiste has collaborated with scholars based in Belgium, United States and Spain. Frequent co-authors include Solange Peters, Suresh Senan, Keith M. Kerr, Keunchil Park, Joachim von Pawel, Fabrice Barlési, Matthijs Oudkerk, David Waller, Carles Escriu and Pieter E. Postmus. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.